New hope for aplastic anemia: drug combo aims to cut transfusion needs
NCT ID NCT07548671
First seen Apr 28, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study tests whether adding enarodustat to standard cyclosporine treatment helps people with newly diagnosed transfusion-dependent non-severe aplastic anemia. About 90 adults who cannot have a stem cell transplant will receive either the combo or cyclosporine alone. The goal is to see if the combination improves blood counts and reduces the need for red blood cell transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.